EICHOR
● Recruiting
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
Condition: HCC · Hepatitis B Virus Related Hepatocellular Carcinoma · Hepatocellular Carcinoma · Sponsor: SCG Cell Therapy Pte. Ltd.
About this study
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
This description comes directly from the study's public registry record.
Talk to the study team
SCG Cell Therapy · 021-50339500 · clinicaltrials@scgcell.com
Always discuss trial participation with your own doctor first.
Locations (7)
| Beijing | Beijing, Beijing Municipality, China | Recruiting |
| Guangzhou | Guangzhou, Guangdong, China | Recruiting |
| Zhengzhou | Zhengzhou, Henan, China | Recruiting |
| Changchun | Changchun, Jilin, China | Recruiting |
| Shenyang | Shenyang, Liaoning, China | Recruiting |
| Ji'nan | Ji'nan, Shandong, China | Recruiting |
| Shanghai | Shanghai, Shanghai Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06617000